LivaNova Valuation Multiples Likely to Increase Amid Steady Progress, Stifel Says In Bullish Initiation
-Analyst Rick Wise initiated coverage of LivaNova with a Buy rating and $115 price target.
-LivaNova, formed following the merger of Cyberonics and Sorin in 2015
-Co is divesting its slower-growth, lower-margin cardiac rhythm management business; recruiting an efficient management team and enacting three growth-enhancing tuck-in acquisitions,
-This work has has laid the foundation for strong top- and bottom-line growth and growth-enhancing pipeline investments — and it hasn't been factored into the stock price, the analyst said.
-LivaNova is an equally compelling margin expansion story, with a 70-percent-plus gross margin likely by 2022 alongside equally impressive operating margin expansion, the analyst said.
-LivaNova shares have gained about 20 percent year-to-date.
I've been seeing this ticker come across and thinking each time it was Live Nation. Turns out LIVN is Liva Nova just a terrible name. Is it Latin? I have no idea what these guys do even after the initiation by the Steifel analyst. So more research is needed here... In general heart related accessories can make you money in the market, I remember one called BEAT... they act like a hybrid health equipment/ bio stock- they unveil new products like new drugs, without some of the outright risk of a Bio play such as a CRSPR stock..
-Analyst Rick Wise initiated coverage of LivaNova with a Buy rating and $115 price target.
-LivaNova, formed following the merger of Cyberonics and Sorin in 2015
-Co is divesting its slower-growth, lower-margin cardiac rhythm management business; recruiting an efficient management team and enacting three growth-enhancing tuck-in acquisitions,
-This work has has laid the foundation for strong top- and bottom-line growth and growth-enhancing pipeline investments — and it hasn't been factored into the stock price, the analyst said.
-LivaNova is an equally compelling margin expansion story, with a 70-percent-plus gross margin likely by 2022 alongside equally impressive operating margin expansion, the analyst said.
-LivaNova shares have gained about 20 percent year-to-date.
I've been seeing this ticker come across and thinking each time it was Live Nation. Turns out LIVN is Liva Nova just a terrible name. Is it Latin? I have no idea what these guys do even after the initiation by the Steifel analyst. So more research is needed here... In general heart related accessories can make you money in the market, I remember one called BEAT... they act like a hybrid health equipment/ bio stock- they unveil new products like new drugs, without some of the outright risk of a Bio play such as a CRSPR stock..
